title: Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals.
abstract: The therapeutic potential of recombinant human interleukin-11 (rhIL-11) was tested in a neutropenic rat model that mimics the clinical consequences of myelosuppressive chemotherapy complicated by Pseudomonas aeruginosa sepsis. rhIL-11-treated animals (150 micrograms/kg intravenously every 24 h for 3 days) had reduced endotoxin levels (P < .05) and less pulmonary edema fluid (P < .001) and were protected (P < .01) against thinning and necrosis of the intestinal mucosa compared with the control group. The survival rate in rhIL-11-treated animals was 40% (19/47), whereas it was 0 (0 of 19) in the control group (P < .01). The addition of ciprofloxacin (10 mg/kg every 12 h) resulted in a survival rate of 9 (60%) of 15, while the combination of rhIL-11 and ciprofloxacin resulted in 100% survival (15/15; P < .05). These results indicate that rhIL-11 supports mucous membrane integrity of the alimentary tract and decreases the systemic inflammatory response to experimental gram-negative infection in immunocompromised animals.
authors.affiliation: Division of Infectious Diseases, University School of Medicine, Providence, Rhode Island, USA. Steven__Opal@brown.edu
authors.forename: S M
authors.initials: SM
authors.lastname: Opal
authors.forename: J W
authors.initials: JW
authors.lastname: Jhung
authors.forename: J C
authors.initials: JC
authors.lastname: Keith
authors.forename: J E
authors.initials: JE
authors.lastname: Palardy
authors.forename: N A
authors.initials: NA
authors.lastname: Parejo
authors.forename: L D
authors.initials: LD
authors.lastname: Young
authors.forename: A
authors.initials: A
authors.lastname: Bhattacharjee
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000401:mortality; D002939:Ciprofloxacin / Q000627:therapeutic use; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D006801:Humans; D016867:Immunocompromised Host; D017370:Interleukin-11 / Q000627:therapeutic use*; D009503:Neutropenia; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000401:mortality; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy*
chemical_list: D000890:Anti-Infective Agents; D017370:Interleukin-11; D011994:Recombinant Proteins; D002939:Ciprofloxacin; C105308:oprelvekin